NovaBridge Biosciences (NBP) Shares Outstanding (Weighted Average) (2017 - 2025)
NovaBridge Biosciences (NBP) reported Shares Outstanding (Weighted Average) of $220.3 million for Q4 2025, up 183549010.0% year-over-year from N/an in Q4 2024, and up 275323565.0% quarter-over-quarter from $80.0 in Q3 2025.
NovaBridge Biosciences (NBP) Shares Outstanding (Weighted Average) (2017 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has 9 years of Shares Outstanding (Weighted Average) data on file, last reported at $220.3 million in Q4 2025.
- Shares Outstanding (Weighted Average) for Q4 2025 came in at $220.3 million, up 183549010.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $220.3 million (up 183549010.0% YoY), and the FY2025 annual result was $220.3 million, up 183549010.0% from the prior year.
- Shares Outstanding (Weighted Average) improved to $220.3 million in Q4 2025 per NBP's latest filing, from $80.0 in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $220.3 million in Q4 2025 and troughed at $20.0 in Q1 2025.
- A 5-year average of $50.8 million and a median of $13.1 million in 2021 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) slumped 100.0% in 2024, then jumped 183549010.0% in 2025.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $27.3 million in 2021, then slipped by 2.35% to $26.7 million in 2022, then retreated by 0.37% to $26.6 million in 2023, then slumped by 100.0% to $120.0 in 2024, then jumped by 183549010.0% to $220.3 million in 2025.
- Business Quant data shows NBP's Shares Outstanding (Weighted Average) at $220.3 million in Q4 2025, $80.0 in Q3 2025, and $50.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 417.01 Bn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 928.40 Mn |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - | 220.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 220.26 Mn |
| Sep 30, 2025 | 80.00 |
| Jun 30, 2025 | 50.00 |
| Mar 31, 2025 | 20.00 |
| Dec 31, 2024 | 120.00 |
| Sep 30, 2024 | 210.00 |
| Jun 30, 2024 | 100.00 |
| Mar 31, 2024 | 50.00 |
| Dec 31, 2023 | 26.59 Mn |
| Sep 30, 2023 | 192.92 Mn |
| Jun 30, 2023 | 191.33 Mn |
| Dec 31, 2022 | 26.68 Mn |
| Dec 31, 2021 | 27.33 Mn |
| Jun 30, 2021 | 26.13 Mn |
| Dec 31, 2020 | 529.64 |
| Sep 30, 2020 | 15.31 Mn |
| Jun 30, 2020 | 17.19 Mn |
| Dec 31, 2019 | 1.05 Mn |
| Dec 31, 2018 | 944,299.88 |
| Dec 31, 2017 | 867,958.51 |